Download PDF
Semin Neurol 2004; 24(1): 5-16
DOI: 10.1055/s-2004-829584
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

A History of Treatments for Myasthenia Gravis

John Carl Keesey1
  • 1Department of Neurology, School of Medicine, University of California, Los Angeles, California
Further Information

Publication History

Publication Date:
01 July 2004 (online)

    Permissions and Reprints

Much of the improvement in the treatment of myasthenia gravis (MG) over the past 125 years can be attributed to the effectiveness of general medical measures such as advances in respiratory care and the discovery of antibiotics. Although MG became the model of an antibody-mediated autoimmune disease in the 1970s (the most documented antigen being the muscle acetylcholine receptor at the neuromuscular junction), the pathogenesis of MG has not been the rationale for most treatments found to be useful for this disease. The serendipitous benefit of anticholinesterases for MG in the 1930s subsequently focused attention on the neuromuscular junction. The beginnings of the controversy over thymectomy for MG in the 1940s and 1950s preceded the discovery in 1960 of the function of the thymus. Before the autoimmune pathogenesis of MG was known, adrenocorticotropic hormone (ACTH) and steroids for MG were tried for reasons that turned out to be incorrect. Further immunosuppressive treatments for MG were largely empirical, following their use in organ transplantation and other autoimmune diseases. More specific treatments, based on our knowledge of pathogenesis, are still experimental but hopefully will be the history of the future.

KEYWORDS

History - myasthenia - treatment

REFERENCES

  • 1 Keesey J. Myasthenia Gravis, An Illustrated History. Roseville, CA; Publishers Design Group 2002
    Google Scholar
  • 2 Erb W H. Handbook of Electrotherapeutics. Pützel L, trans. New York; William Woods 1883
    Google Scholar
  • 3 Viets H R. A historical review of myasthenia gravis from 1672 to 1900.  JAMA. 1953;  153 1273-1280
    PubMedGoogle Scholar
  • 4 Goldflam S. Ueber einen scheinbar heilbaren bulbärparalytischen symptomencomplex mit betheiligung der extremitäten.  Deutsche Z Nervenheilkunde. 1893;  4 312-352
    PubMedGoogle Scholar
  • 5 Goldflam S. Weiteres uber die asthenische lahmung nebst einem obductionsbefund. Neurologishes Zentralblatt 1902 21 97-107 490-496
    Google Scholar
  • 6 Oppenheim H. Die Myasthenische Paralyse (Bulbärparalyse ohne anatomischen Befund. Berlin; S. Karger 1901
    Google Scholar
  • 7 Campbell H, Bramwell E. Myasthenia gravis.  Brain. 1900;  23 277-336
    PubMedGoogle Scholar
  • 8 Starr M A. Myasthenia gravis.  J Nerv Ment Dis. 1912;  39 721-731
    PubMedGoogle Scholar
  • 9 Oppenheim H. Weitere beitrag sur lehre von den acuten, night-eitrigen encephalitis und der poliencephalomyelitis.  Deutsche Z Nervenheilkunde. 1899;  15 1-21
    PubMedGoogle Scholar
  • 10 Weigert C. Pathologisch-anatomischer Beitrag zur Erb'schen Krankheit (Myasthenia gravis).  Neurologisches Zentralblatt. 1901;  20 596-601
    PubMedGoogle Scholar
  • 11 Schumacher C H, Roth P. Thymektomie bei einem Fall von Murbus Basedowi mit Myasthenia.  Mitteilungen Grensgebeiten Medizin Chirurgie. 1913;  25 746-765
    PubMedGoogle Scholar
  • 12 Keschner M, Strauss I. Myasthenia gravis.  AMA Arch Neurol Psychiatry. 1927;  17 337-376
    PubMedGoogle Scholar
  • 13 Kennedy F S, Moersch F P. Myasthenia gravis: a clinical review of eighty-seven cases observed between 1915 and early part of 1932.  Can Med Assoc J. 1935;  37 216-223
    PubMedGoogle Scholar
  • 14 Shaw L E. A case of bulbar paralysis without structural changes in the medulla.  Brain. 1890;  13 96-99
    PubMedGoogle Scholar
  • 15 Goerig M, Filos K, Ayisi K W. George Edward Fell and the development of respiratory machines. In: Atkinson RS, Boulton TB The History of Anesthesia. Park Ridge, NJ; Parthenon Publishing Group 1987: 386-393
    Google Scholar
  • 16 Drinker P, McKhann C F. The use of a new apparatus for the prolonged administration of artificial respiration.  JAMA. 1929;  92 1658-1660
    PubMedGoogle Scholar
  • 17 Secher O. The polio epidemic in Copenhagen 1952. In: Atkinson RS, Boulton TB The History of Anesthesia. Park Ridge, NJ; Parthenon Publishing Group 1987: 425-432
    Google Scholar
  • 18 Remen L. Zur pathogenese und therapie der myasthenia gravis pseudoparalytica.  Deutsche Z Nervenheilkunde. 1932;  128 66-78
    PubMedGoogle Scholar
  • 19 Boothby W M, Adams M, Power M H et al.. Myasthenia gravis: second report on the effect of treatment with glycine.  Mayo Clin Proc. 1932;  7 737-756
    PubMedGoogle Scholar
  • 20 Walker M B. Treatment of myasthenia gravis with physostigmine.  Lancet. 1934;  1 1200-1201
    PubMedGoogle Scholar
  • 21 Keesey J C. Contemporary opinions about Mary Walker, a shy pioneer of therapeutic neurology.  Neurology. 1998;  51 1433-1439
    PubMedGoogle Scholar
  • 22 Everts W H. The treatment of myasthenia gravis by the oral administration of Prostigmin.  Bull Neurol Inst. 1935;  4 523-530
    PubMedGoogle Scholar
  • 23 Viets H R. Myasthenia gravis.  JAMA. 1945;  127 1089-1096
    PubMedGoogle Scholar
  • 24 Eaton L M. Care of the patient who has myasthenia gravis.  Med Clin North Am. 1947;  31 907-923
    PubMedGoogle Scholar
  • 25 Keesey J C. “Crisis” in myasthenia gravis: an historical perspective.  Muscle Nerve. 2002;  26 1-3
    CrossrefPubMedGoogle Scholar
  • 26 Laurent L PE, Walther W W. The influence of large doses of potassium chloride on myasthenia gravis.  Lancet. 1935;  1 1434-1435
    PubMedGoogle Scholar
  • 27 Minot A S, Dodd K, Riven S S. Use of guanidine hydrochloride in treatment of myasthenia gravis.  JAMA. 1939;  113 553-559
    PubMedGoogle Scholar
  • 28 Blalock A, Mason M F, Morgan H J, Riven S S. Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed.  Ann Surg. 1939;  110 544-561
    CrossrefPubMedGoogle Scholar
  • 29 Blalock A, Harvey A M, Ford F R, Lilienthal J L. The treatment of myasthenia gravis by removal of the thymus gland: preliminary report.  JAMA. 1941;  117 1529-1533
    CrossrefPubMedGoogle Scholar
  • 32 Clagett O T, Eaton L M. Surgical treatment of myasthenia gravis.  J Thorac Surg. 1947;  16 62-80
    PubMedGoogle Scholar
  • 30 Kirschner P A. Alfred Blalock and thymectomy for myasthenia gravis.  Ann Thorac Surg. 1987;  43 348-349
    PubMedGoogle Scholar
  • 31 Keynes G. The results of thymectomy in myasthenia gravis.  BMJ. 1949;  1 611-616
    PubMedGoogle Scholar
  • 33 Eaton L M, Clagett O T. Thymectomy in the treatment of myasthenia gravis. Results in seventy-two cases compared to one hundred and forty-two control cases.  JAMA. 1950;  142 963-967
    PubMedGoogle Scholar
  • 34 Eaton L M, Clagett O T. Present status of thymectomy in treatment of myasthenia gravis.  Am J Med. 1955;  19 703-717
    PubMedGoogle Scholar
  • 35 Givel J C. Historical review. In: Givel JC Surgery of the Thymus. Berlin; Springer-Verlag 1990: 1-9
    Google Scholar
  • 36 Schwab R S, Leland C C. Sex and age in myasthenia gravis as critical factors in incidence and remission.  JAMA. 1953;  153 1270-1280
    PubMedGoogle Scholar
  • 37 Grob D. Myasthenia gravis, current status of pathogenesis, clinical manifestations, and management.  J Chronic Dis. 1958;  8 536-566
    CrossrefPubMedGoogle Scholar
  • 38 Perlo V P, Poskanzer D C, Schwab R S, Viets H R, Osserman K E, Genkins G. Myasthenia gravis: evaluation of treatment in 1,355 patients.  Neurology. 1966;  16 431-439
    PubMedGoogle Scholar
  • 39 Bernatz PE in discussion following Buckingham JM . Howard F M, Bernatz P E, Payne W S, Harrison E G, O'Brien P C, Weiland L H. The value of thymectomy in myasthenia gravis: a computer-assisted matched study.  Ann Surg. 1976;  184 453-458
    PubMedGoogle Scholar
  • 40 Kirschner P A. The history of surgery of the thymus gland.  Chest Surg Clin N Am. 2000;  10 153-165
    PubMedGoogle Scholar
  • 41 Osserman K E, Teng P, Kaplan L I. Studies in myasthenia gravis. Preliminary report on therapy with Mestinon bromide.  JAMA. 1954;  155 961-965
    PubMedGoogle Scholar
  • 42 Comroe J H, Todd J, Gammon G D et al.. The effect of di-isopropyl-fluorophosphate (DFP) upon patients with myasthenia gravis.  Am J Med Sci. 1946;  212 641-651
    PubMedGoogle Scholar
  • 43 Westerberg M R, Luros J T. The clinical use of hexaethyl tetraphosphate in myasthenia gravis.  Med Bull (Ann Arbor). 1948;  14 15-17
    PubMedGoogle Scholar
  • 44 Burgen A SV, Keel C A, McAlpine D. Tetra-ethylpyrophosphate in myasthenia gravis.  Lancet. 1948;  1 519-521
    PubMedGoogle Scholar
  • 45 Rider J A, Schulman S, Richter R B, Moeller H C, DuBois K P. Treatment of myasthenia gravis with octamethyl phyrophosphoramide.  JAMA. 1951;  145 967-972
    PubMedGoogle Scholar
  • 46 Artusio J F, Riker W F, Wescoe W C. Studies on the inter-relationship of certain cholinergic compounds. IV. Anti-curare action in anesthetized man.  J Pharmacol Exp Ther. 1950;  100 227-237
    PubMedGoogle Scholar
  • 47 MacFarlane D W, Pelikan W e, Unna K R. Evaluation of curarizing drugs in man. V. Antagonism to curarizing effects of d-tubocurarine by neostigmine, m-hydroxy phenyltrimethylammonium and m-hydroxy phenylethyldimethylammonium.  J Pharmacol Exp Ther. 1950;  100 382-392
    PubMedGoogle Scholar
  • 48 Westerberg M R, Magee K R, Shideman F E. Effect of 3-hydroxy phenyldimethylethyl ammonium chloride (Tensilon) in myasthenia gravis.  Med Bull (Ann Arbor). 1951;  17 311-316
    PubMedGoogle Scholar
  • 49 Westerberg M R, Magee K R, Shideman F E. Effect of Tensilon in myasthenia gravis.  Neurology. 1953;  3 302-305
    PubMedGoogle Scholar
  • 50 Tether J E. Mestinon in myasthenia gravis (preliminary report).  Dis Nerv Syst. 1954;  15 227-231
    PubMedGoogle Scholar
  • 51 Schwab R S, Timberlake W H. Pyridostigmin (Mestinon) in the treatment of myasthenia gravis.  N Engl J Med. 1954;  251 271-272
    PubMedGoogle Scholar
  • 52 Westerberg M R, Magee K R. Mestinon in the treatment of myasthenia gravis.  Neurology. 1954;  4 762-771
    PubMedGoogle Scholar
  • 53 Schwab R S. WIN 8077 in the treatment of sixty myasthenia gravis patients, a twelve-month report.  Am J Med. 1955;  19 734-736
    PubMedGoogle Scholar
  • 54 Westerberg M R. Clinical evaluation of ambenonium (Mysuran) chloride.  AMA Arch Neurol Psychiatry. 1956;  75 91-94
    PubMedGoogle Scholar
  • 55 Kraupp O, Stumpf C, Herzfeld E, Pillat B. Pharmakologische Eigenschaften einiger langwirksamer Cholinesterase-Hemmkörper aus der Reihe der Polymethylen-bis-(Carbaminoyl-m-Trimethylammoniumphenole).  Arch Int Parmacodyn Ther. 1955;  102 281-303
    PubMedGoogle Scholar
  • 56 Pateisky K, Herzfeld E, Stumpf C. Der Effekt von Polymethylen-bis-(N-methyl-m- trimethylammonium-phenolen) BC40, BC47, BC58 auf Cholinesteraseaktivität und Muskeltätigkeit bei Myasthenia gravis pseudparalytica.  Wein KlinWochenschr. 1957;  69 2-7
    PubMedGoogle Scholar
  • 57 Hoefer P FA, Aronow H, Rowland L P. Long-acting compounds, especially BC 51, in the treatment of myasthenia gravis. In: Viets HR Myasthenia Gravis. The Second International Symposium Proceedings Springfield, IL; Charles C. Thomas 1961: 545-555
    Google Scholar
  • 58 Schwarz H. Urecholine in myasthenia gravis.  Can Med Assoc J. 1955;  72 346-351
    PubMedGoogle Scholar
  • 59 Gottlieb B, Laurent L PE. Spironolactone in the treatment of myasthenia gravis.  Lancet. 1961;  2 528-529
    PubMedGoogle Scholar
  • 60 Satoyoshi E, Murakami K, Okazaki T. Triamterene in the treatment of myasthenia gravis.  Lancet. 1964;  15 741-742
    PubMedGoogle Scholar
  • 61 Somers J E, Irwin R L, Shy G M. The use of lycoramine derivatives in myasthenia gravis.  Neurology. 1963;  13 543-553
    PubMedGoogle Scholar
  • 62 Foldes F F, Foldes V M, McNall P G. The use of echothiophate in myasthenia gravis.  Clin Pharmacol Ther. 1966;  7 620-630
    PubMedGoogle Scholar
  • 63 Hofmann W W. Action of veratrine on human skeletal muscle with special reference to myasthenia gravis.  Neurology. 1958;  8 417-432
    PubMedGoogle Scholar
  • 64 Flacke W, Caviness V S, Samaha F G. Treatment of myasthenia gravis with germine diacetate.  N Engl J Med. 1966;  275 1207-1214
    PubMedGoogle Scholar
  • 65 Marsh D O. Adrenal therapy for neuromuscular disease including myasthenia gravis from 1896.  N Y State J Med. 1974;  74 1974-1976
    PubMedGoogle Scholar
  • 66 Simon H E. Myasthenia gravis, effect of treatment with anterior pituitary extract: preliminary report.  JAMA. 1935;  104 2065-2066
    PubMedGoogle Scholar
  • 67 Schlezinger N S. Evaluation of therapy in myasthenia gravis.  Arch Intern Med. 1940;  65 60-77
    PubMedGoogle Scholar
  • 68 Torda C, Wolff H G. Effects of adrenocorticotrophic hormone on neuro-muscular function in patients with myasthenia gravis.  Proc Soc Exp Biol Med. 1949;  71 432-435
    PubMedGoogle Scholar
  • 69 Millikan C H, Eaton L M. Clinical evaluation of ACTH and cortisone in myasthenia gravis.  Neurology. 1951;  1 145-152
    CrossrefPubMedGoogle Scholar
  • 70 Grob D, Harvey A M. Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis, and report on onset of myasthenia gravis during prolonged cortisone administration.  Bull Johns Hopkins Hosp. 1952;  91 124-136
    PubMedGoogle Scholar
  • 71 Freydberg L D. The place of corticotrophin in the treatment of myasthenia gravis.  Ann Intern Med. 1960;  52 806-818
    PubMedGoogle Scholar
  • 72 Schlezinger N S. Present status of therapy in myasthenia gravis.  JAMA. 1952;  148 508-513
    PubMedGoogle Scholar
  • 73 Osserman K E. Myasthenia Gravis. New York; Grune & Stratton 1958: 159
    Google Scholar
  • 74 von Reis G, Liljestrand Å, Matell G. Results with ACTH and spironolactone in severe cases of myasthenia gravis.  Acta Neurol Scand Suppl. 1965;  13 463-471
    PubMedGoogle Scholar
  • 75 Simpson J. Myasthenia gravis: a new hypothesis.  Scott Med J. 1960;  5 419-436
    PubMedGoogle Scholar
  • 76 Osserman K E, Genkins G. Studies in myasthenia gravis. Short-term massive corticotrophin therapy.  JAMA. 1966;  198 699-702
    CrossrefPubMedGoogle Scholar
  • 77 Grob D, Namba T. Corticotrophin in generalized myasthenia gravis. Effect of short, intensive courses.  JAMA. 1966;  198 703-707
    CrossrefPubMedGoogle Scholar
  • 78 Thevènard A. Carotid sinus denervation in myasthenia gravis. In: Viets HR Myasthenia Gravis. The Second International Symposium Proceedings Springfield, IL; Charles C Thomas 1961: 624-633
    Google Scholar
  • 79 Kjaer M. Myasthenia gravis and myasthenic syndromes treated with prednisone.  Acta Neurol Scand. 1971;  47 464-474
    PubMedGoogle Scholar
  • 80 Warmolts J R, Engel W K. Benefit from alternate-day prednisone in myasthenia gravis.  N Engl J Med. 1972;  286 17-20
    CrossrefPubMedGoogle Scholar
  • 81 Jenkins R B. Treatment of myasthenia gravis with prednisone.  Lancet. 1972;  1 765-767
    PubMedGoogle Scholar
  • 82 Shy G M, Brendler S, Rabinovitch R, McEachern D. Effects of cortisone in certain neuromuscular disorders.  JAMA. 1950;  144 1353-1358
    PubMedGoogle Scholar
  • 83 Strauss A JL, Seegal B C, Hsu K C, Burkholder P M, Nastuk W L, Osserman K E. Immunofluorescence demonstration of a muscle binding, complement fixing serum globulin fraction in myasthenia gravis.  Proc Soc Exp Biol Med. 1960;  105 184-191
    PubMedGoogle Scholar
  • 84 Miller J FAP. Immunological function of the thymus.  Lancet. 1961;  2 748-749
    PubMedGoogle Scholar
  • 85 Wolf S M, Rowland L P, Schotland D L, McKinney A S, Hoefer P FA, Aranow H. Myasthenia as an autoimmune disease. Clinical aspects.  Ann N Y Acad Sci. 1966;  135 517-535
    PubMedGoogle Scholar
  • 86 Rowland L P. Immunosuppressive drugs in treatment of myasthenia gravis.  Ann N Y Acad Sci. 1971;  183 351-357
    PubMedGoogle Scholar
  • 87 Delwaide P J, Salmon J, van Cauwenberger H. Premiers essais de traitement de la myasthenia par azathioprine.  Acta Neurol Psychiatr Belg. 1967;  67 701-712
    PubMedGoogle Scholar
  • 88 Guille-Minault C. Premiers essais de traitement de la myasthenia par azathioprine.  Gaz Med Fr. 1968;  75 6545
    PubMedGoogle Scholar
  • 89 Mertens H G, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents.  Eur Neurol. 1969;  2 321-339
    CrossrefPubMedGoogle Scholar
  • 90 Hertel G, Mertens H G, Reuther P, Ricker K. The treatment of myasthenia gravis with azathioprine. In: Dau PC Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA; Houghton Mifflin 1979: 315-328
    Google Scholar
  • 91 Matell G, Bergström K, Franksson C et al.. Effects of some immunosuppressive procedures on myasthenia gravis.  Ann N Y Acad Sci. 1976;  274 659-676
    CrossrefPubMedGoogle Scholar
  • 92 Szobor A, Petrányi G. Immunosuppressive therapy of myasthenia gravis.  Acta Med Acad Sci Hung. 1970;  27 397-411
    PubMedGoogle Scholar
  • 93 Nouza K, Šmat V. The favourable effect of cyclophosphamide in myasthenia gravis.  Rev Fr Etud Clin Biol. 1968;  13 161-163
    PubMedGoogle Scholar
  • 94 Perez M C, Buot W L, Mercado-Danguilan C, Bababaldo Z G, Renales L D. Stable remission in myasthenia gravis.  Neurology. 1981;  31 32-37
    CrossrefPubMedGoogle Scholar
  • 95 Goulon M, Elkharrat D, Gajdos P, Lokiec F, Morel E. Preliminary results in myasthenia gravis treated with cyclosporin.  Ann N Y Acad Sci. 1987;  505 857-860
    PubMedGoogle Scholar
  • 96 Tindall R SA, Rollins J A, Phillips J T, Greelee R G, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.  N Engl J Med. 1987;  316 719-724
    CrossrefPubMedGoogle Scholar
  • 97 Nyberg-Hansen R, Gjerstad L. Myasthenia gravis treated with cyclosporin.  Acta Neurol Scand. 1988;  77 307-313
    PubMedGoogle Scholar
  • 98 Hauser R A, Malek A R, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil.  Neurology. 1998;  51 912-913
    PubMedGoogle Scholar
  • 99 Chaudhry V, Cornblath D R, Griffin J W, O'Brien R, Drachman D B. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.  Neurology. 2001;  56 94-96
    CrossrefPubMedGoogle Scholar
  • 100 Ciafaloni E, Massey J M, Tucker-Lipscomb B, Sanders D B. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.  Neurology. 2001;  56 97-99
    CrossrefPubMedGoogle Scholar
  • 101 Riven S S, Mason M F. The treatment of myasthenia gravis.  South Med J. 1937;  30 181-190
    PubMedGoogle Scholar
  • 102 Aring C D. Treatment of myasthenia gravis with the Roentgen ray.  Ohio State Med J. 1943;  39 241-244
    PubMedGoogle Scholar
  • 103 Keynes G. Investigations into thymic disease and tumour formation.  Br J Surg. 1955;  42 449-462
    PubMedGoogle Scholar
  • 104 Grob D. Course and management of myasthenia gravis.  JAMA. 1953;  153 529-532
    PubMedGoogle Scholar
  • 105 Henson R A, Stern G A, Thompson V C. Thymectomy for myasthenia gravis.  Brain. 1965;  88 11-28
    PubMedGoogle Scholar
  • 106 Schwab R S. Evaluation of one hundred and thirty thymectomies. In: Viets HR Myasthenia Gravis. The Second International Symposium Proceedings Springfield, IL; Charles C Thomas 1961: 597-601
    Google Scholar
  • 107 Schulz M D, Schwab R S. Results of thymic (mediastinal) irradiation in patients with myasthenia gravis.  Ann N Y Acad Sci. 1971;  183 303-307
    PubMedGoogle Scholar
  • 108 Philllips T L, Buschke F. The role of radiation therapy in myasthenia gravis.  Calif Med. 1967;  106 282-289
    PubMedGoogle Scholar
  • 109 Currier R D, Routh A, Hickman B T, Douglas M A. Thymus irradiation for myasthenia gravis.  Radiology. 1983;  146 199-201
    PubMedGoogle Scholar
  • 110 Engel W K, Lichter A S, Dalakas M. Spenic and total-body irradiation treatment of myasthenia gravis.  Ann N Y Acad Sci. 1981;  377 744-754
    PubMedGoogle Scholar
  • 111 Durelli L, Ferrio M F, Urgesi A, Poccardi G, Ferrero B, Bergamini L. Total body irradiation for myasthenia gravis: a long-term follow-up.  Neurology. 1993;  43 2215-2221
    PubMedGoogle Scholar
  • 112 Stricker E, Thölen H, Massini M A, Stauf H. The effect of haemodialysis in myasthenia gravis.  J Neurol Neurosurg Psychiatry. 1960;  23 291-294
    PubMedGoogle Scholar
  • 113 Hedger R W, Davis F A, Schwartz F D, Ing T S. Improvement of myasthenia gravis by hemodialysis in a patient with chronic renal failure.  Ann Intern Med. 1971;  75 749-752
    PubMedGoogle Scholar
  • 114 Patten B M. A hypothesis to account for the Mary walker phenomenon.  Ann Intern Med. 1975;  82 411-415
    PubMedGoogle Scholar
  • 115 Lefvert A K, Matell G. Thoracic duct lymph drainage in myasthenia gravis: clinical effect and kinetic studies of the acetylcholine receptor antibody. In: Dau PC Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA; Houghton Mifflin 1979: 151-160
    Google Scholar
  • 116 Tindall S C, Peters B H, Caverley J R, Sarles H E, Fish J C. Thoracic duct lymphocyte depletion in myasthenia gravis.  Arch Neurol. 1973;  29 202-203
    PubMedGoogle Scholar
  • 117 Bergstrom K, Franksson C, Matell G et al.. Drainage of thoracic duct lymph in twelve patients with myasthenia gravis.  Eur Neurol. 1975;  13 19-30
    PubMedGoogle Scholar
  • 118 Lindstrom J M, Seybold M E, Lennon V A, Whittingham S, Duane D D. Antibody to acetylcholine receptor in myasthenia gravis.  Neurology. 1976;  26 1054-1059
    CrossrefPubMedGoogle Scholar
  • 119 Pinching A F, Peters D K, Newsom-Davis J. Remission of myasthenia gravis following plasma exchange.  Lancet. 1976;  2 1373-1376
    PubMedGoogle Scholar
  • 120 Dau P C, Lindstrom J M, Cassel C K, Denys E H, Shev E E, Spitler L E. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.  N Engl J Med. 1977;  297 1134-1140
    CrossrefPubMedGoogle Scholar
  • 121 Pirofsky B, Reid R H, Bardana E J, Baker R L. Antithymocyte antiserum therapy in myasthenia gravis.  Postgrad Med J. 1976;  52(suppl 5) 112-117
    PubMedGoogle Scholar
  • 122 Pirofsky B, Reid R H, Bardana E J, Baker R L. Myasthenia gravis treated with purified antithymocyte antiserum.  Neurology. 1979;  29 112-116
    PubMedGoogle Scholar
  • 123 Leövey A, Szobor A, Szegedi G, Szathmáry I, Petrányi G. Myasthenia gravis: ALG treatment of seriously ill patients.  Eur Neurol. 1975;  13 422-432
    PubMedGoogle Scholar
  • 124 Genkins G, Paptestas A E, Kornfeld P, Horowitz S H. Studies in myasthenia gravis: staging and gamma globulin. In: Dau PC Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA; Houghton Mifflin 1979: 144-150
    Google Scholar
  • 125 Gajdos P, Outin H, Elkharrat D et al.. High-dose intravenous gammaglobulin for myasthenia gravis.  Lancet. 1984;  1 406-407
    PubMedGoogle Scholar
  • 126 Arsura E L, Bick A, Brunner N G, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis.  Arch Intern Med. 1986;  146 1365-1368
    CrossrefPubMedGoogle Scholar

John KeeseyM.D. 

1144 Iliff Street

Pacific Palisades, CA 90272